NCT00366379View on ClinicalTrials.gov

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

GK Activator (2)

25-200mg po bid for 20 weeks

Trial Locations (21)

1002

Riga

1038

Riga

3001

Jelgava

10138

Tallinn

23249

Richmond

29651

Greer

31238

Chihuahua City

32765

Oviedo

42086

Pachuca

44340

Guadalajara

44650

Guadalajara

44718

Canton

47714

Evansville

50406

Tartu

50708

Tartu

51014

Tartu

59701

Butte

79707

Midland

83687

Nampa

85225

Chandler

97239

Portland

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00366379 - A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes. | Biotech Hunter | Biotech Hunter